Nuclea Biotechnologies raises more funds; Roche in-licenses sequencing tech from ASU;

@FierceBiotech: Pfizer, Exonhit partner on Alzheimer's biomarkers. More | Follow @FierceBiotech

@ JohnCFierce: In their settlement deal--spelled out in an 8K--Onyx gets U.S. co-promo rights to regorafenib. | Follow @JohnCFierce

@RyanMFierce: I saw twitter action on this fertility startup OvaScience a while ago, but @scottkirsner is 1st to write an article Article | Follow @RyanMFierce

@MaureenFierce: @LifeSciVC: E&Y says 44% of drugs in dev are for oncology. @dereklowe asks, is that too many, too few or just right? Article Follow @MaureenFierce

> Researchers at the Maine Medical Center Research Institute have discovered a potential cancer biomarker by detecting a specific protein in patients' blood. While the protein was first suspected to be a breast cancer biomarker, researchers have found elevated levels in skin, prostate and lung cancer patients as well. The name of the specific protein was not disclosed in news reports. Article

> A BARDA-funded program is set to enter the next phase of a research project to develop a test that could quickly and easily identify whether a person had been exposed to dangerous levels of radiation following a nuclear incident. Report

> Paris-based biotech Exonhit Therapeutics has established a research pact with Pfizer to discover Alzheimer's disease biomarkers via a pilot study. The study will use Exonhit's Genome-Wide SpliceArray platform (GWSA), which monitors splicing variants in RNA. News

> Nuclea Biotechnologies has bumped a recent round to $6.4 million. Report

> Roche has struck a deal to in-license DNA sequencing tech from Arizona State University. Story

> A group of 83 biotech companies from across the Hudson Valley in New York have formed a consortium to set up a training center to help local biotech firms train their workers. Release

> Aduro BioTech has treated the first patient in a mid-stage 2 pancreatic cancer clinical trial of two cancer vaccines: Aduro's CRS-207 and GVAX Pancreas Cancer Vaccine. Release

Pharma News

@FiercePharma: Merck persuaded an Australian appeals court to overturn a Vioxx damages award of $259,400 News | Follow @FiercePharma

> Third jury rules against Teva, Baxter in hep C suit. Report

> Australian court tosses Vioxx ruling against Merck. News

> Bayer to pay $160M as part of Onyx settlement. Item

> Bayer inks pledge to J.V. with Russia's Yunona. News

> Pfizer sues Merck to block Lipitor/Zetia combo pill. Piece

> Dendreon to amp up DTC support for Provenge. Article

Medical Device News

> Report: Cook stent meets safety, effectiveness goals. Item

> CorMatrix gets FDA OK for CorMatrix ECM in carotid repair. Article

> Cambridge Heart reports more good news with MTWA test. Story

> Covidien, Aircraft Medical ink deal. News

> MicroPhage, Cardinal Health ink deal on MRSA test. More

> Invacare to lay off 50. More

Drug Delivery News

> Nano-therapy that cooks deadly brain tumors advances in Germany. More

> Unigene forms joint venture to develop oral peptide drugs with Nordic Bioscience. Story

> Zosano inks Asian deal worth $32.5M-plus for drug patch tech. Report

And Finally... An international team of investigators have been exploring how cancer cells change to protect themselves, offering drug developers some insights into the defense mechanisms. Release

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.